Evommune Signs $20 Million License Deal With Hinova

Evommune entered a license agreement with Hinova Pharmaceuticals to develop, manufacture and sell Hinova’s glue degraders. Evommune will gain exclusive access to Vav Guanine Nucleotide Exchange Factor 1 degraders.